Regeneron Pharmaceuticals and Sanofi announced that the European Commission approved the PD-1 inhibitor Libtayo (cemiplimab) for the first-line treatment of adults with non-small cell lung cancer (NSCLC) whose tumor cells have ≥50% PD-L1 expression and no EGFR, ALK or ROS1 aberrations. The EC also approved Libtayo in advanced basal cell carcinoma (BCC).
German biotech CureVac NV said the company’s Covid-19 vaccine was only 47 percent effective in a late-stage trial, missing the study’s main goal and throwing in doubt the potential delivery of hundreds of millions of doses to the European Union.
A deal on an intellectual property waiver for Covid-19 vaccines at the World Trade Organization (WTO) was no closer to acceptance on May 31 despite Washington’s backing, due to expected scepticism about a new draft, sources close to the talks told Reuters.
AstraZeneca’s top-selling Tagrisso drug was approved for use in the European Union to treat patients with a type of early-stage lung cancer, the company said on May 28.
The U.S. Food and Drug Administration gave an emergency use authorization to the antibody treatment developed by Vir Biotechnology and GlaxoSmithKline for treating mild-to-moderate Covid-19 in people aged 12 years and older.
Taiwan directly accused China for the first time on May 26 of blocking a deal with Germany’s BioNTech SE for Covid-19 vaccines, in an escalating war of words after Beijing offered the shots to the island via a Chinese company.
A lawyer for the European Union accused AstraZeneca on May 26 of failing to respect the company’s contract with the 27-nation bloc for the supply of Covid-19 vaccines and asked a Belgian court to impose a large fine on the Anglo-Swedish drug firm.
The European Union expects to have received more than a billion doses of Covid-19 vaccines by the end of September from four drugmakers, according to a document presented to EU leaders on Tuesday.
The Covid-19 vaccine of AstraZeneca Plc and Oxford University works well as a third booster dose, stepping up antibodies to the coronavirus spike protein among participants in a study, the Financial Times said on May 19.
United Nations Secretary-General Antonio Guterres called on May 12 for the need to double the capacity of Covid-19 vaccine production and for fairer redistribution of the shots in the developing world, which faces new waves of the coronavirus.